U.S. FDA approves Takeda's lung cancer drug as 2nd-line treatment

April 28 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd

said on Friday that the U.S. Food and Drug

Administration approved its lung cancer drug, almost three

months after the company acquired the drug's developer, Ariad

Pharmaceuticals Inc.

Read more